Serological Responses to a Norovirus Nonstructural Fusion Protein after Vaccination and Infection

Clinical and Vaccine Immunology

Volumn 23, Issue 2, 2016, Pages 181-183

  Hesse, Shayla ^a   Neill, Frederick H ^a   Estes, Mary K ^a   Shanker, Sreejesh ^a   Prasad, B V Venkataram ^a   Ferreira, Jennifer ^b   Atmar, Robert L ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b EMMES CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRAL PROTEIN; VIRUS ANTIBODY; VIRUS FUSION PROTEIN; VIRUS LIKE PARTICLE VACCINE; VIRUS VACCINE;

BLOOD; CALICIVIRIDAE INFECTIONS; CHEMISTRY; EVALUATION STUDY; FECES; HUMAN; IMMUNOASSAY; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; NOROVIRUS; SENSITIVITY AND SPECIFICITY; VIROLOGY;

ADMINISTRATION, INTRANASAL; ANTIBODIES, VIRAL; CALICIVIRIDAE INFECTIONS; FECES; HUMANS; IMMUNOASSAY; NOROVIRUS; SENSITIVITY AND SPECIFICITY; VACCINES, VIRUS-LIKE PARTICLE; VIRAL FUSION PROTEINS; VIRAL NONSTRUCTURAL PROTEINS; VIRAL VACCINES;

EID: 84958674452     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00595-15     Document Type: Article

References (8)

1. Hall AJ, Lopman BA, Payne DC, Patel MM, Gastanaduy PA, Vinje J, Parashar UD. 2013. Norovirus disease in the United States. Emerg Infect Dis 19:1198-1205. http://dx.doi.org/10.3201/eid1908.130465.
2. Ramani S, Atmar RL, Estes MK. 2014. Epidemiology of human norovi-ruses and updates on vaccine development. Curr Opin Gastroenterol 30: 25-33. http://dx.doi.org/10.1097/MOG.0000000000000022.
3. Glass RI, Parashar UD, Estes MK. 2009. Current concepts: norovirus gastroenteritis. N Engl J Med 361:1776-1785. http://dx.doi.org/10.1056/NEJMra0804575.
4. Richardson C, Ba rgatze RF, Goodwin R, Mendelman PM. 2013. Norovirus virus-like particle vaccines for the prevention of acute gastroenteritis. Expert Rev Vaccines 12:155-167. http://dx.doi.org/10.1586/erv.12.145.
5. Atmar RL, Opekun AR, Gilger MA, Estes MK, Crawford SE, Neill FH, Ramani S, Hill H, Ferreira J, Graham DY. 2014. Determination of the 50% human infectious dose for Norwalk virus. J Infect Dis 209: 1016-1022. http://dx.doi.org/10.1093/infdis/jit620.
6. Bernstein DI, Atmar RL, Lyon GM, Treanor JJ, Chen WH, Jiang X, Vinjé J, Gregoricus N, Frenck RW, Jr., Moe CL, Al-Ibrahim MS, Barrett J, Ferreira J, Estes MK, Graham DY, Goodwin R, Borkowski A, Clemens R, Mendelman PM. 2015. Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults. J Infect D is 211:870-878. http://dx.doi.org/10.1093/infdis/jiu497.
7. Ajami NJ, Barry MA, Carillo B, Muhaxhiri Z, Neill FH, Prasad BVV, Opekun A, Gilger MA, Graham DY, Atmar RL, Estes MK. 2012. Antibody responses to norovirus genogroup GI.1 and GII.4 proteases in volunteers administered Norwalk virus. Clin Vaccine Immunol 19:1980-1983. http://dx.doi.org/10.1128/CVI.00411-12.
8. Atmar RL , Bernstein DI, Harro CD, Al Ibrahim MS, Chen WH, Ferreira J, Estes MK, Graham DY, Opekun AR, Richardson C, Mendelman PM. 2011. Norovirus vaccine protects against experimental human Norwalk virus illness. N Engl J Med 365:2178-2187. http://dx.doi.org/10.1056/NEJMoa1101245.